Merck Sharp & Dohme LLC — Sponsor Intelligence | 293 EU Trials

Filter these 293 trials by condition, phase, country and more.

Open in Search →

293 Registered trials

92 Recruiting

189 Completed trials

25 Countries active

165 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase I (Other)

Phase III: 117 Phase II/III: 13 Phase II: 62 Phase I/II: 33 Phase III/IV: 5 Phase I: 24 Phase I (Other): 36 Phase I (FiH): 3

Oversight events:

4 serious breaches 72 temporary halts 6 urgent safety measures 9 unexpected events 9 corrective measures across 37 trials

View oversight register →

100%

189 of 189 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer metastatic 8 Renal cell carcinoma 8 Non-small cell lung cancer 6 Non-alcoholic steatohepatitis 4 Respiratory syncytial virus infection 4 Non-small cell lung cancer stage IV 3 Pulmonary arterial hypertension 3 Rheumatoid arthritis 3 Bladder cancer 3 Hormone receptor positive HER2 negative breast cancer 3 Prostate cancer metastatic 3 Hormone receptor positive breast cancer 2

Top IMPs

PEMBROLIZUMAB 114 LENVATINIB 26 SACITUZUMAB TIRUMOTECAN 23 PEMBROLIZUMAB, VIBOSTOLIMAB 13 PEMBROLIZUMAB, FAVEZELIMAB 12 BELZUTIFAN 11 OLAPARIB 11 MK-4830 10 MRNA-4157 9 IFINATAMAB DERUXTECAN 8 PATRITUMAB DERUXTECAN 8 PEMBROLIZUMAB, QUAVONLIMAB 8

All trials — page 3

293 total

A clinical study of tulisokibart in people with rheumatoid arthritis (MK-7240-014) Recruiting

2025-521745-25-00 Phase II 3 countries TULISOKIBART
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD-1… Recruiting

2023-506384-34-00 Phase I (FiH) 4 countries SKB410; ZILOVERTAMAB VEDOTIN
A clinical study of patritumab deruxtecan in people with breast cancer Recruiting

2024-514376-40-00 Phase II 1 country PATRITUMAB DERUXTECAN; PEMBROLIZUMAB
A clinical study of MK-2214 in people with Alzheimer’s disease (MK-2214-004) Recruiting

2024-519190-19-00 Phase II 3 countries FLORQUINITAU (18F); MK-2214
A clinical study of MK-1084 with targeted therapy and chemotherapy in people with colorectal cancer (MK-1084-012). Recruiting

2024-517232-22-00 Phase III 9 countries BEVACIZUMAB; MK-1084
A clinical study of ifinatamab deruxtecan and pembrolizumab with or without chemotherapy in people with esophageal cancer (MK-3475-06E) Recruiting

2024-514273-22-00 Phase I/II 5 countries IFINATAMAB DERUXTECAN; PEMBROLIZUMAB
A clinical study of MK-5684 in people with certain solid tumors (MK-5684-015) Recruiting

2024-519563-18-00 Phase II/III 1 country OPEVESOSTAT TOSILATE
A clinical study of combination therapies in people with kidney cancer (MK-3475-03C) Recruiting

2024-516437-12-00 Phase I/II 3 countries BELZUTIFAN; N-(4-FLUOROPHENYL)-N-(4-((7-METHOXY-6-(METHYLCARBAMOYL)QUINOLIN-4- Y…
A clinical study of treatments for non-small cell lung cancer (MK-3475-01H) Recruiting

2024-518761-10-00 Phase II 6 countries IFINATAMAB DERUXTECAN; RALUDOTATUG DERUXTECAN
A clinical study of sacituzumab tirumotecan and pembrolizumab in people with endometrial cancer (MK-2870-033) Recruiting

2024-519331-42-00 Phase III 16 countries PEMBROLIZUMAB; SACITUZUMAB TIRUMOTECAN
A clinical study of ifinatamab deruxtecan to treat metastatic prostate cancer (MK 2400 01A) Recruiting

2024-516036-94-00 Phase I/II 7 countries IFINATAMAB DERUXTECAN; OPEVESOSTAT TOSILATE
A clinical study of V940 and pembrolizumab in people with melanoma (V940-012) Recruiting

2024-519605-36-00 Phase II 7 countries MRNA-4157; PEMBROLIZUMAB
A clinical study of MK-4646 in people with HIV (MK-4646-003) Recruiting

2025-521102-17-00 Phase I (Other) 1 country
A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK‑8294 Monotherapy in Advanced Solid Tumors Recruiting

2024-516870-31-00 Phase I 1 country
A clinical study of sacituzumab tirumotecan with or without pembrolizumab in people with breast cancer (MK-2870-011) Recruiting

2024-516834-36-00 Phase III 13 countries PEMBROLIZUMAB; SACITUZUMAB TIRUMOTECAN
A clinical study of patritumab deruxtecan (HER3-DXd) in children with cancer (MK-9999-01C) Recruiting

2024-518771-66-00 Phase I/II 12 countries PATRITUMAB DERUXTECAN
Phase 3 Study of I-DXd Versus Docetaxel in mCRPC Recruiting

2024-517423-40-00 Phase III 13 countries IFINATAMAB DERUXTECAN
A clinical study of V940 and BCG in people with bladder cancer (V940-011) Recruiting

2024-517335-46-00 Phase II 9 countries MRNA-4157
A clinical study of the V540C vaccine in healthy adults (V540C-003) Recruiting

2024-518863-36-00 Phase I 1 country
A clinical study of MK-3120 in people with solid tumors (MK-3120-002) Recruiting

2024-516817-19-00 Phase I/II 3 countries SKB410
A clinical study of zilovertamab vedotin with R-CHP treatment in people with diffuse large B-cell lymphoma (MK-2140-011) Recruiting

2024-515526-89-00 Phase II 5 countries ZILOVERTAMAB VEDOTIN
A clinical study of V940 and pembrolizumab to treat lung cancer (V940-009) Recruiting

2023-506327-29-00 Phase III 14 countries MRNA-4157; PEMBROLIZUMAB
A clinical study of zilovertamab vedotin in people with large B-cell lymphoma (MK-2140-010) Recruiting

2024-515566-13-00 Phase III 11 countries ZILOVERTAMAB VEDOTIN
A clinical study of MK-6070 and ifinatamab deruxtecan in people with small cell lung cancer (MK-6070-002) Recruiting

2024-517926-25-00 Phase I/II 1 country GOCATAMIG; IFINATAMAB DERUXTECAN

Showing 49–72 of 293 trials

← All sponsors A–Z